Marco Boorsma

Mr. Boorsma is Partner at Forbion Capital Partners and joined the firm in 2007. He has a background in molecular biology and biotechnology and brings operational and business development experience from both small and large businesses. Before joining Forbion Mr. Boorsma was Business Development Director and project manager at DSM Pharmaceutical Products and scientist at Cytos Biotechnology in Switzerland.
Mr. Boorsma serves on Milestone’s Board of Directors since 2017. He also serves on the Board of RSPR Pharma, Prexton Therapeutics, and Engene, and is Observer to the Board of Exosome Diagnostics and Oxyrane. Previously, Mr. Boorsma was instrumental in the start-up and served on the board of Dezima Pharma, which was sold to Amgen, and on the Board of Akarna Therapeutics, which was sold to Allergan.

After obtaining a master’s degree in molecular biology from the University of Groningen, Mr. Boorsma received his PhD in biotechnology from the ETH Institute for Technology in Zürich, and completed part of his research at the Laboratory of Molecular Biology of the Medical Research Council in Cambridge, UK.